A major limit for in vivo studies is the different cellular distribution of the IgE high-affinity receptor. In mice, the IgE high-affinity receptor is not expressed on monocytes/DCs, Langerhans cells, or eosinophils whereas it is in humans.

The model enables the production of a fully human IgE-FcεRI complex combined with a human-like expression of a FcεRI receptor.

hIgE/hFcεR1 model features

  • Human-like cellular distribution (i.e., mast cells, basophils, monocytes/DCs, Langerhans cells, and eosinophils) of the FcεR1 receptor due to the presence of a minimal human promoter that drives its expression
  • Physiological regulation and expression of the chimeric IgE/FcεR1 complex [humanized IgE/FcεR1 interactive domains (i.e., IgE Fc region and FcεR1 α-chain), and murine IgE Fab region and FcεR1 β- and γ-chains]

Validation

Related resources and publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results

Discover related products to

hIgE/hFcεR1

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mouse
Reporter
IL-4

IL-4-IRES-eGFP

The reliable monitoring and sorting of IL-4-secreting cells allows you to efficiently delineate the immune response polarization toward the Th2 pathway.

Mouse
Reporter
Foxp3

Foxp3-IRES-mRFP

This reliable Foxp3 reporter mouse allows you to efficiently monitor/sort Foxp3-expressing cells from different lymphocyte lineages & lymphoid organs

Mouse
HSA
PK/PD
Immunodeficient

HSA/hFcRn-Rag1-KO

This upgraded, immunocompromised Rag1-/- version of our HSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.

BRGSF
Immunodeficient
Mouse

BRGSF

Compared to NOD-SCID and NSG, the BRGSF mouse represents the most adapted animal model to study and predict human immune responses in vivo.

Mouse
HIS
BRGSF
Immunodeficient

BRGSF-A2-HIS

BRGSF-A2-HIS mice possess the most functional reconstituted human immune system. HLA molecules on thymic epithelial cells hinder T-cell cross-reactivity.

Mouse
Inflammation
TNF

hTNF-α

The hTNF-α model provides new opportunities for assessment of anti-TNF therapies.

Mouse
CD4
Inflammation

hCD4

The human CD4 mouse model allows in vivo efficacy and safety assessment of anti-human CD4 compounds.

Mouse
ICP
PD-1
GITR
ICP (multi-target)

hPD-1/hGITR/hGITRL

The hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Mouse
ICP
VISTA
ICP (single-target)

hVISTA

The hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

Mouse
ICP
STING
ICP (single-target)

hSTING

The hSTING mouse enables the in vivo assessment of agents and therapies targeting  the human immune checkpoint STING in fully immunocompetent mice.

Mouse
ICP
OX40
ICP (single-target)

hOX40

The hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

Mouse
ICP
GITR
ICP (single-target)

hGITR

The hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Mouse
ICP
CTLA-4
ICP (single-target)

hCTLA-4

The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Mouse
ICP
CD39
ICP (single-target)

hCD39

The hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Mouse
ICP
CD28
ICP (single-target)

hCD28

The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Mouse
ICP
PD-1
PD-L1
ICP (multi-target)

hPD-1/hPD-L1

The hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Mouse
ICP
PD-1
Lag3
ICP (multi-target)

hPD-1/hLAG3

The hPD-1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Mouse
ICP
PD-1
VISTA
ICP (multi-target)

hPD-1/hVISTA

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Mouse
ICP
PD-1
TIM3
ICP (multi-target)

hPD-1/hTIM3

The hPD-1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Mouse
ICP
Reporter
GITR
Foxp3

hGITR/Foxp3

The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.

Mouse
ICP
GITR
GITRL
ICP (multi-target)

hGITR/hGITRL

The hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

Mouse
ICP
CTLA-4
PD-1
ICP (multi-target)

hPD-1/hCTLA-4

The hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Mouse
ICP
CTLA-4
Lag3
ICP (multi-target)

hCTLA-4/hLAG3

The hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

T-cell engager
CD3
Mouse

hCD3ε

hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

Mouse
PD-1
ICP
ICP (single-target)

hPD-1

The hPD-1 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 in fully immunocompetent mice.

Mouse
HSA
PK/PD

HSA/hFcRn

Use this double humanized HSA/hFcRn mouse model for accurate and predictive PK/PD studies of albumin- and FcRn-binding compounds.

Mouse
BRGSF
HIS
Immunodeficient

BRGSF-HIS

BRGSF-HIS mice possess the most functional reconstituted human immune system currently on the market and are highly relevant for translational research.

CD3
Mouse
CD28
T-cell engager

hCD3ε/hCD28

hCD3ε  immunocompetent mice enable the efficacy assessment of T-cell engagers, to  study cancer cell recognition, immunosuppressant therapies, etc.

Humanized IgE/FcεR1 mouse model

Get in touch about

Let us know how we can help

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.